Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Qiagen CFO Sees COVID Diagnostics Volatility Continuing In 2022

Executive Summary

Qiagen’s doubled-down focus on PCR technologies in late 2019 proved to be fortuitous, but future growth will come from many other drivers, says CFO Roland Sackers.

You may also be interested in...



Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio

Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.

Olympus Medical Follows The Patient Pathway In New Strategic Plan

Having divested non-medical imaging a year ago, Olympus Corp is putting its foot to the floor in refocusing on its medical portfolio. It has set global ambitions of strengthening its coverage of unmet needs and of playing a major role in reshaping health care delivery.

Cardio Industry Puts Weight Behind UK Call For National CVD Strategy

Better uptake of medtech in tackling cardiovascular disease can bring benefits across the entire pathway of care, say UK CVD companies, who are urging the government to improve levels of technology adoption.

Topics

Related Companies

UsernamePublicRestriction

Register

MT144918

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel